RAPT Therapeutics Inc (FRA:0RA)
€ 1.73 0 (0%) Market Cap: 56.69 Mil Enterprise Value: -32.34 Mil PE Ratio: 0 PB Ratio: 0.66 GF Score: 41/100

Rapt Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript

Jun 12, 2023 / 08:20PM GMT
Release Date Price: €18.8 (-2.59%)
Corinne Jenkins
Goldman Sachs - Analyst

Great, so we can get started now. I wanted to say thank you to Brian and Rodney, who are joining us here from the RAPT team.

Questions & Answers

Corinne Jenkins
Goldman Sachs - Analyst

And maybe we'll just kick it off with an overview. So if you could, just a brief overview of the company, particularly focused on what you see as key value drivers over the next 12 to 24 months.

Brian Wong
RAPT Therapeutics, Inc. - President, CEO, & Director

Yes, sure. First of all, thanks, Corinne, for the invitation. Thanks to your group as well. So RAPT is a publicly traded company that focuses on oral small molecules that target key driver -- immunological drivers for both inflammation and cancer.

Through our own internal discovery, we have two lead assets, one is called RPT193. This is a once-daily oral that targets the same pathway as drugs such as dupilumab. But we think that the oral convenience would allow -- would be very attractive for patients with a broad

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot